Active Biotech

0.05 SEK

+0.42 %

Less than 1K followers

ACTI

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

+0.42 %

+19.60 %

+4.78 %

-19.93 %

-63.58 %

-33.25 %

-84.53 %

-90.22 %

-98.84 %

Active Biotech operates in the pharmaceutical industry and focuses on the development of innovative treatments for cancer and autoimmune diseases. The company researches new therapies that can improve patient outcomes and quality of life. The project portfolio includes both small, orally active immunomodulatory molecules and antibody-based immunotherapy. The company operates globally. Active Biotech was founded in 1998 and is headquartered in Lund.

Market cap

127.06M SEK

Turnover

517.98K SEK

Revenue

-

EBIT %

-

P/E

-

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

7.5

2026

Interim report Q1'26

20.5

2026

General meeting '26

20.8

2026

Interim report Q2'26

All

Webcasts

Press releases

ShowingAll content types

Press release2/13/2026, 12:08 PM

Redeye: Active Biotech (Q4 Review): Tasqinimod Recruiting Again

Regulatory press release2/12/2026, 7:30 AM

Active Biotech Year End Report 2025

Press release2/10/2026, 10:30 AM

Active Biotech receives positive feedback on its clinical study with tasquinimod in myelofibrosis

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release1/30/2026, 10:30 AM

Number of shares and votes in Active Biotech

Regulatory press release1/21/2026, 3:15 PM

Active Biotech's nomination committee appointed

Regulatory press release12/10/2025, 7:00 PM

Active Biotech announces outcome in the rights issue

Press release11/25/2025, 9:00 AM

Active Biotech’s patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Regulatory press release11/25/2025, 7:30 AM

The subscription period in Active Biotech’s rights issue begins today

Press release11/24/2025, 8:30 AM

Positive preclinical tasquinimod data in myelofibrosis published in Blood Advances

Regulatory press release11/20/2025, 2:45 PM

Active Biotech publishes information document regarding rights issue

Regulatory press release11/19/2025, 11:00 AM

Extraordinary General Meeting of Active Biotech AB

Press release11/10/2025, 8:45 AM

Redeye: Active Biotech (Q3 Review) - Rights Issue Funds 2026-2027

Regulatory press release11/6/2025, 7:30 AM

Active Biotech Interim Report Q3 2025

Press release11/3/2025, 3:30 PM

Preclinical data of tasquinimod in combination with T cell activation to be presented at ASH 2025

Regulatory press release10/17/2025, 6:35 PM

NOTICE OF EXTRAORDINARY GENERAL MEETING

Regulatory press release10/17/2025, 6:30 PM

Active Biotech announces a fully secured rights issue of approximately SEK 70 million

Press release9/10/2025, 11:00 AM

Positive results from Active Biotech’s clinical phase I LION study to be presented at AAO 2025 in October

Press release8/25/2025, 2:40 PM

Redeye: Active Biotech Q2 2025 - On the Eve of a Laquinimod Deal

Regulatory press release8/21/2025, 6:30 AM

INTERIM REPORT Q2 2025

Press release7/8/2025, 6:30 AM

Active Biotech provides status update of its development programs

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.